PUBLISHER: DelveInsight | PRODUCT CODE: 1120523
PUBLISHER: DelveInsight | PRODUCT CODE: 1120523
DelveInsight's, "Behcet disease - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Behcet disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Behcet disease was first described in 1937 by Hulusi Behcet from Istanbul, who described three patients with oral and genital ulcerations, uveitis, and erythema nodosum. Other clinical features were identified later and were added to the disease spectrum. Behcet disease is an auto-inflammatory systemic vasculitis of unknown etiology. It is characterized by mucocutaneous manifestations, including recurrent oral and genital ulcerations, ocular manifestations, especially chronic relapsing uveitis and systemic vasculitis involving arteries and veins of all sizes. It is also known as Behcet syndrome and malignant aphthosis.
"Behcet disease - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Behcet disease pipeline landscape is provided which includes the disease overview and Behcet disease treatment guidelines. The assessment part of the report embraces, in depth Behcet disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Behcet disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Behcet disease R&D. The therapies under development are focused on novel approaches to treat/improve Behcet disease.
This segment of the Behcet disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Canakinumab is a human monoclonal antibody designed to target interleukin-1B with high affinity and selectivity, in turn preventing it from activating its downstream receptors. This mode of action makes canakinumab an effective anti-inflammatory molecule.
This segment of the report provides insights about the Behcet disease drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the therapies for Behcet disease. The companies which have their Behcet disease drug candidates in the most advanced stage, i.e. Phase II include Novartis.
DelveInsight's report covers around 5+ products under different phases of clinical development like:
Behcet disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Behcet disease therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Behcet disease drugs.